Peripheral T- and B-cell immune signatures associated with response to vedolizumab in ulcerative colitis
Inflammatory Bowel Diseases · 2026-11-06
DOI: 10.1093/ibd/izag242 ↗Abstract
Abstract Background and aims Vedolizumab (VDZ) blocks integrin α4β7-MAdCAM-1 interactions, limiting leukocyte entry into the gut, yet peripheral-blood immune correlates of clinical response in ulcerative colitis (UC) remain unidentified. Methods Peripheral blood mononuclear cells from healthy controls (HCs) and patients with UC, stratified by VDZ exposure and clinical response, were analyzed using mass cytometry (cytometry by time-of-flight). A 38-marker panel enriched for integrins, chemokine receptors, and activation markers was applied. Major immune populations were interrogated using lineage-specific opt-SNE and FlowSOM clustering. Results The dataset included 26 HCs, 30 VDZ-naive UC (Nancy index ≥ 2), 8 VDZ-treated non-responders (Nancy index ≥ 2), and 8 VDZ-treated responders (Nancy index <2). No significant differences were detected in myeloid, NK-cell, or TCRγδ+ T-cell compartments. Integrin α4β7+ cells were detected across multiple immune lineages and were enriched in the B-cell compartment. Between-group differences were observed in the CD4+ T-cell and B-cell compartments. VDZ responders showed enrichment of an α4β7+ effector memory CD4+ T-cell subset compared with VDZ-naive UC. In parallel, responders exhibited reduced frequencies of class-switched plasmablast and activated B-cell populations relative to VDZ-naive UC. Integrin-pairing analysis demonstrated that these B-cell populations contained both α4β7+ and α4β1+ cells. In contrast, VDZ non-responders showed enrichment of an α4β7+ atypical-like IgA+ memory B-cell subset relative to responders, VDZ-naive UC, and HCs. Conclusions Clinical response and non-response to VDZ in UC are associated with distinct circulating T- and B-cell immune phenotypes. Peripheral-blood immunophenotyping may identify correlates of response and non-response. Prospective studies are needed to determine whether these signatures are predictive before VDZ initiation or reflect pharmacodynamic changes after treatment.
EUVIMED